The CDMO platform is designed to support structured, multi-year supply programmes, offering integrated development-to-commercial manufacturing capabilities. The company is also evaluating capacity enhancement and technology investments aligned with its expanding CDMO opportunity pipeline.
Chairman and Managing Director Sushil Suri said, “This mandate represents an important milestone in the evolution of Morepen’s manufacturing platform. It reflects the confidence global customers place in our quality systems, regulatory track record, and execution capabilities.”Read more: Vikram Solar shares worth over ₹2,000 crore free up for trade as lock-in ends; stock below IPO price
The company described the mandate as one of the largest single CDMO contracts in its history, marking a step-up in its global manufacturing scale.Suri added, “We view CDMO as a natural extension of our established API strengths, creating additional avenues of scale, stability, and long-term value creation while continuing to reinforce our core businesses.”
The engagement builds on Morepen’s existing active pharmaceutical ingredient (API) manufacturing platform and its regulatory accreditations, including approvals from the US Food and Drug Administration (USFDA), WHO-GMP and European authorities.
Read more: Stocks To Buy: Morgan Stanley bets on this multibagger defence stock to rise another 20%
Morepen operates as a vertically integrated pharmaceutical and healthcare company, supplying APIs, branded generics, medical devices and consumer wellness products across more than 90 countries.
Following the announcement, shares of the company were trading 44.95 as of 9.36 am. The stock has surged 31.55% in the past month.
